Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  March Villalba, José A ^a   Martínez Jabaloyas, José M ^a   Herrero, María J ^b   Santamaria, Jose ^a   Aliño, Salvador F ^b   Dasí, Francisco ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865168940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043470     Document Type: Article

References (29)

1. Jemal A, Siegl R, Xu J, Ward E, ((2010)) Cancer statistics. CA Cancer J Clin 60:: 277--300.
2. Hoffman RM, ((2011)) Screening for prostate cancer. N Engl J Med 365:: 2013--2019.
3. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, et al. ((2011)) Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 18:: 5875--5883.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. ((2004)) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350:: 2239--2246.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. ((2009)) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:: 1320--1328.
6. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, et al. ((2010)) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:: 725--732.
7. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al ((2009)) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:: 1310--1319.
8. Wilt TJ, MacDonald R, Rutks I, Sham- liyan TA, Taylor BC, ((2008)) Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:: 435--448.
9. Tricoli JV, Schoenfeldt M, Conley BA, ((2004)) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10:: 3943--3953.
10. Dasi F., Garcia-Granero E, Lledo S, Ripoll R, Marugan M, et al. ((2001)) Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a single blood test to monitor disease in patients. Lab Invest 81:: 767--769.
11. Lledo SM, Garcia-Granero E, Dasi F, Ripoll R, Garcia SA, et al. ((2004)) Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Color Dis 6:: 236--242.
12. Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, et al. ((2006)) Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 97:: 1366--1373.
13. Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, et al. ((2010)) A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol 10:: 46.
14. Silva JM, Dominguez G, Silva J, Garcia JM, Sánchez A, et al. ((2001)) Detection of Epithelial Messenger RNA in the Plasma of Breast Cancer Patients Is Associated with Poor Prognosis Tumor Characteristics. Clin Cancer Res 7:: 2821--2825.
15. Dalle Carbonare L, Gasparetto A, Donatelli L, Dellantonio A, et al. (2011) Telomerase mRNA detection in serum of patients with prostate cancer. Urol Oncol. Feb 24. Epub ahead of print] doi: 10.1016/j.urolonc.2010.12.017.
16. Dasi F, Martínez-Rodes P, March JA, Santamaria J, Martinez-Jabaloyas M, et al. ((2006)) Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in the Plasma of Patients with Prostate Cancer. Ann N Y Acad Sci 1075:: 204--210.
17. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, et al. ((2008)) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 14:: 7444--7451.
18. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf 13 June 2012].
19. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, et al. ((2009)) Prostate specific antigen best practice statement: 2009 update. J Urol 182:: 2232--2241.
20. March-Villalba JA, Martinez-Jabaloyas JM, Herrero MJ, Santamaria J, Aliño SF, et al. (2012) Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opin Biol Ther 12 Suppl 1:S 69-77.
21. Fleischhacker M, Schmidt B, ((2007)) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775:: 181--232.
22. Schwarzenbach H, Hoon DSB, Pantel K, ((2011)) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:: 426--437.
23. Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, et al. ((2007)) Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 72 (Suppl 1):: 45--51.
24. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, et al. ((2007)) A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep 17:: 541--548.
25. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, et al. ((2011)) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:: 1608--1615.
26. Altimari A, Grigioni AD, Benedettini E, Gabusi E, Schiavina R, et al. ((2008)) Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 129:: 756--762.
27. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, et al. ((2011)) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50 (Suppl 1):: 61--75.
28. Bjartell A, Montironi R, Berney DM, Egevad L, ((2011)) Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 50 (Suppl 1):: 76--84.
29. Roobol MJ, Haese A, Bjartell A, ((2011)) Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 50 (Suppl 1):: 85--89.